Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PLEC | Q15149 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930611 | 0.98 | KDM4E (0.59) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL189858 | 0.98 | KDM4E (0.59) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL1316369 | 0.96 | KDM4E (0.57) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL16474145 | 0.77 | ALOX5 (0.59) | KDM4EALDH1A1ALOX5MPI | |
| SCHEMBL194708 | 0.77 | KDM4E (0.44) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL19577293 | 0.74 | KDM4E (0.61) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL7070837 | 0.73 | KDM4E (0.42) | KDM4ETP53TSHRGAAMEN1 | |
| SCHEMBL1618278 | 0.72 | KDM4E (0.59) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL31091767 | 0.72 | KDM4E (1.00) | KDM4ETP53TSHRGAAMAPK1 | |
| SCHEMBL1101962 | 0.72 | KDM4E (1.00) | KDM4ETP53TSHRGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153889-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9968602-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| CN-107567437-A | Crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione sodium salt, pharmaceutical preparation containing it and process for its production | 麦翠奥制药公司 | 2018-01-09 | — | — | CN | disclosed |
| EP-2389364-B1 | NEW METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE | ABIDOPHARMA PL SP Z O O (PL) | 2016-10-26 | — | — | EP | disclosed |
| US-9101629-B2 | Method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine | ABIDOPHARMA PL SP. Z O.O. (PL) | 2015-08-11 | — | — | US | disclosed |
| US-20140113902-A1 | METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE | Abidopharma PL SP. Z.O.O. (PL) | 2014-04-24 | — | — | US | disclosed |
| US-20140030317-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | Occhiuti & Rohlicek LLP | 2014-01-30 | — | — | US | disclosed |
| US-8536171-B2 | Method for obtaining 5-amino 2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine | Abidopharma PL SP. Z.O.O. (PL) | 2013-09-17 | — | — | US | disclosed |
| EP-2389364-A2 | NEW METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE | Abidopharma Pl SP. Z.O.O (PL) | 2011-11-30 | — | — | EP | disclosed |
| US-20110275642-A1 | NEW METHOD FOR OBTAINING 5-AMINO 2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE | Abidopharma PL SP. Z.O.O. (PL) | 2011-11-10 | — | — | US | disclosed |
| US-20090018137-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1924274-A4 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA INC (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1924274-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | Bach Pharma, Inc (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7326690-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007018546-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20050288291-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-20020198208-A1 | MEDICINAL PREPARATION AND PROCESS FOR MANUFACTURING THEREOF | ABIDOV, MUSA TAZHUDINOVICH (RU) | 2002-12-26 | — | — | US | disclosed |
| US-6489326-B1 | SODIUM NUCLEINATE, 2-AMINO-1,2,3,4-TETRAHYDROPHTHALAZINE-1,4-DIONE SODIUM SALT DIHYDRATE, USED AS AN IMMUNOMODULATOR, WHICH ALSO HAS ANTIINFLAMMATORY AND ANTIOXIDANT PROPERTIES | Pavlov, Anatoliy Ivanovich (RU) | 2002-12-03 | — | — | US | disclosed |
| EP-1203587-A1 | A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF | Abidov, Musea Tazhudinovich (RU) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275642-A1 | NEW METHOD FOR OBTAINING 5-AMINO 2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE | ADH1C, SCN5A, ADH1A | KDM4E 2263/4885TP53 2286/4885TSHR 3071/4885 |
| US-20180153889-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | NFE2L2, GPX4, TXNRD2 | KDM4E 2063/4885TP53 89/4885TSHR 3785/4885 |
| US-20140113902-A1 | METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE | SCN5A, SLC5A2, KCNJ2 | KDM4E 1852/4885TP53 3567/4885TSHR 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.